NXL
Nexalin Technology, Inc.
NXL offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over NXL overall, supported by lower modeled downside and stronger fundamentals.
NXL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
NXL's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NXL PE Valuation
NXL has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NXL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect NXL's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NXL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.63 | +$6.47 |
| Q2 2026 | -$14.10 | +$9.00 |
| Q1 2026 | -$13.80 | +$11.40 |
| Q4 2025 | -$15.00 | +$9.90 |
| Q3 2025 | -$20.10 | -$0.68 |
| Q2 2025 | -$23.10 | -$1.28 |
| Q1 2025 | -$25.20 | -$5.18 |
| Q4 2024 | -$24.90 | -$6.00 |
NXL is still losing money, but far less than before: $13.63 per share over the past year, against $34.20 at its worst in late 2021.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over NXL on earnings quality, reporting a profit while its opponent remains loss making.
NXL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $78.3K | +331% |
| Q2 2026 | $12.2K | -83% |
| Q1 2026 | $15K | -64% |
| Q4 2025 | $171.9K | +532% |
| Q3 2025 | $18.1K | -50% |
| Q2 2025 | $70.6K | +163% |
| Q1 2025 | $41K | -48% |
| Q4 2024 | $27.2K | +32% |
NXL's revenue is recovering but still below its 2022 peak: $78,301 last quarter, up 331% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3332% | +9592 points |
| Q2 2026 | -18480% | -16184 points |
| Q1 2026 | -14180% | -9276 points |
| Q4 2025 | -1404% | +9176 points |
| Q3 2025 | -12924% | -5962 points |
| Q2 2025 | -2296% | +2536 points |
| Q1 2025 | -4904% | -3539 points |
| Q4 2024 | -10579% | -2669 points |
NXL's operating margin was −3332% last quarter, up 9592 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NXL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over NXL on profitability, with a higher operating margin.
NXL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6M | -$121.5K |
| Q2 2026 | -$1.8M | -$884.5K |
| Q1 2026 | -$1.7M | -$286.8K |
| Q4 2025 | -$1.1M | -$13.5K |
| Q3 2025 | -$1.5M | -$666K |
| Q2 2025 | -$917.2K | +$329.3K |
| Q1 2025 | -$1.4M | -$662.9K |
| Q4 2024 | -$1.1M | -$130.4K |
NXL has burned cash in almost every quarter: −$6M over the past year, against −$5M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over NXL on cash generation, producing positive trailing cash flow while its opponent burns cash.
NXL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +71.9K shares |
| 1 year | +48% | +253K shares |
| 3 years | +220% | +534K shares |
| 5 years | +376% | +613K shares |
NXL has 776,657 diluted shares, up 48% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over NXL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NXL Net Leverage
NXL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
NXL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.1 | Oversold |
| Stochastic | 1.3 | Oversold |
NXL's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NXL PE vs Healthcare Sector
NXL has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NXL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.81 | 47% below |
| 20 week MA | $6.97 | 79% below |
| 50 week MA | $12.1 | 88% below |
| 100 week MA | $31.0 | 95% below |
| 200 week MA | $31.2 | 95% below |
NXL is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NXL on trend strength, trading above more of its moving averages.
NXL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $67.5 | $23.4 | -65% |
| 2023 | $23.4 | $12.1 | -48% |
| 2024 | $12.1 | $88.5 | +629% |
| 2025 | $88.5 | $18.9 | -79% |
| 2026 YTD | $18.9 | $1.49 | -92% |
NXL's yearly returns have swung widely, from +629% in 2024 to −79% in 2025. It's down 92% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NXL on returns for 2026, with the stronger performance.